%0 Journal Article
%T Best clinical practice in the treatment of juvenile systemic sclerosis: expert panel guidance - the result of the International Hamburg Consensus Meeting December 2022.
%A Foeldvari I
%A Torok KS
%A Antón J
%A Blakley M
%A Constantin T
%A Cutolo M
%A Denton CP
%A Fligelstone K
%A Hinrichs B
%A Li SC
%A Maillard S
%A Marrani E
%A Moinzadeh P
%A Orteu CH
%A Pain CE
%A Pauling JD
%A Pilkington C
%A Rosser F
%A Smith V
%A Furst DF
%J Expert Rev Clin Immunol
%V 20
%N 4
%D 2024 Apr 27
%M 38149621
%F 5.124
%R 10.1080/1744666X.2023.2298354
%X <B>UNASSIGNED: </B>Juvenile systemic sclerosis (jSSc) is an orphan disease with a prevalence of 3 in 1,000,000 children. Currently there is only one consensus treatment guideline concerning skin, pulmonary and vascular involvement for jSSc, the jSSc SHARE (Single Hub and Access point for pediatric Rheumatology in Europe) initiative, which was based on data procured up to 2014. Therefore, an update of these guidelines, with a more recent literature and expert experience, and extension of the guidance to more aspects of the disease is needed.<BR><B>UNASSIGNED: </B>Treatment options were reviewed, and opinions were provided for most facets of jSSc including general management, some of which differs from adult systemic sclerosis, such as the use of corticosteroids, and specific organ involvement, such as skin, musculoskeletal, pulmonary, and gastroenterology.<BR><B>UNASSIGNED: </B>We are suggesting the treat to target strategy to treat early to prevent cumulative disease damage in jSSc. Conclusions are derived from both expert opinion and available literature, which is mostly based on adult systemic sclerosis (aSSc), given shared pathophysiology, extrapolation of results from aSSc studies was judged reasonable.